Chapman Steven Leonard sold $1.5M of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 5,770 shares of Natera, Inc. (NTRA) at an average of $256.51 ($254.07–$260.49, $1.48M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the CEO’s disclosed open-market sale amount and timing under a 10b5-1 plan; it may slightly influence sentiment but does not change fundamentals based on the provided text.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no new guidance, trial result, deal, or regulatory action in the text.

03

What to watch

The price range of the sale ($254.07 to $260.49) could coincide with normal trading volatility, and the net holdings after the sale (102,973 shares) suggests continued insider exposure.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed late July, with sales executed 2026-07-27 to 2026-07-28.

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $1.48M of NTRA shares via a 10b5-1 plan across two open-market trades in late July.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and it provides no new operational, financial, or regulatory catalyst.

Market effects

Minimal. The disclosure is company-specific and does not introduce a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is pre-arranged under 10b5-1, the market may overreact; the transaction may not reflect negative expectations.

Key entities

  • Natera, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Chapman Steven Leonard

    CEO and President who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.